ionHP Biodecontamination Technology for Aseptic Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ionHP Biodecontamination Technology for Aseptic Systems



The ionHP biodecontamination system by Telstar is used in aseptic enclosures to resolve difficulties associated with hydrogen peroxide biodecontamination processes. The ionHP technology increases the efficacy of the decontamination process and reduces degradation of construction materials by requiring a low concentration of hydrogen peroxide. In addition, the reduced bio-decontamination cycle times are possible since the process efficiency is not affected by temperature and humidity; there is no need to pre-condition the chamber prior to the hydrogen peroxide injection, according to the company.

ionHP can be used in open air and, once ionized, acts like a gas as opposed to a vapor, which offers operational, commercial, and environmental benefits. According to the company, this gives the ionHP a shorter decontamination process time and it does not require special atmospheric conditions, which eliminates the need for the air conditioning units required with traditional systems, reducing equipment cost. The ionHP also uses a base concentration of 7.5% volume, while traditional hydrogen peroxide systems use 30-35%.

This new system is also is more effective due to the positively charged droplets being attracted to the negatively charged surface areas and the ionHP does not leave behind any residue, reducing costs by shortening cleaning activities, the company reports.

Source: Telstar

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here